Indication

As an adjunct to diet in adult patients with genetically confirmed familial chylomicronaemia syndrome (FCS) and at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate.

Medicine details

Medicine name:
volanesorsen sodium (Waylivra)
SMC ID:
SMC2299
Pharmaceutical company
Akcea Therapeutics UK Ltd
BNF chapter
Nutrition and blood
Submission type
Ultra-orphan initial assessment
Publication due date:
09 November 2020
SMC meeting date:
06 October 2020
Patient group submission deadline:
07 September 2020